Normophthal added to Retinalamin for early age-related macular degeneration
Randomized study in people · 2013
- What was studied
- 120 patients with early age-related macular degeneration, 213 eyes: 67 in the combination group and 53 in the Retinalamin group.
- Main finding
- After 40 days, uncorrected visual acuity in the 45–59-year subgroup was 0.62 with adjunctive Normophthal and 0.60 with Retinalamin alone. The author reports no significant additional clinical effect in the oldest subgroup.
Uncorrected visual acuity at day 40, ages 45–59 · 0.62 ± 0.04 with the combination and 0.60 ± 0.04 with Retinalamin alone. The reported pretreatment value was 0.47 ± 0.04.
Reported findings and study design
67 patients received combination treatment and 53 received Retinalamin only. The author describes stratified randomization. Visual testing occurred at baseline, day 40 and three months after treatment.
Population or model 120 patients with early age-related macular degeneration, 213 eyes: 67 in the combination group and 53 in the Retinalamin group.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Study regimen | Both groups received 5 mg Retinalamin by parabulbar injection each day for 10 days. The combination group then received 100 µg Normophthal orally twice daily for 30 days. | |
| Uncorrected visual acuity at day 40, ages 45–59 | 0.62 ± 0.04 with the combination and 0.60 ± 0.04 with Retinalamin alone. The reported pretreatment value was 0.47 ± 0.04. | |
| Oldest subgroup, ages 75–89 | The author reports no significant additional clinical effect with Normophthal in this subgroup. |
The author abstract identifies the Ophthalmology Laboratory of the St. Petersburg Institute of Bioregulation and Gerontology as the research institution. Both groups received Retinalamin.
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- The author reports stratified randomization. Details of concealment and masking are unavailable.
- The 45–59-year result is one age subgroup. The cited values alone do not establish a statistically significant difference between arms.
- The 45-patient 2013 Kazakhstan paper is a separate publication with different authors and group sizes. The available records do not establish cohort overlap.
Source details
Dissertation author abstract · Reproduction of Russian author abstract
Russian author abstract, methods and results on pages 10–21. The full dissertation was unavailable.
Sources checked
Citation
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
A. V. Gorbunov. Normophthal added to Retinalamin for early age-related macular degeneration Candidate of Medical Sciences dissertation author abstract. St. Petersburg, 2013. Catalogue identifier 005531262.
Related compounds
Normophthal
An oral ocular peptide preparation listed as a dipeptide in the Khavinson catalogue. Human studies examined its use alongside conventional care or after injected Retinalamin in age-related macular degeneration.
Retinalamin
A retinal tissue polypeptide extract studied in people with retinal disease, including age-related macular degeneration and pigmentary retinal dystrophy. Studies distinguish injected Retinalamin from oral Normophthal.